Atai Life Sciences N.V. (ETR:9VC)
Germany · Delayed Price · Currency is EUR 3.267
-0.247 (-7.03%)
Aug 14, 2025, 4:00 PM EDT
Atai Life Sciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2020 |
| 2.31 | 0.31 | 0.31 | 0.23 | 20.38 | - | Upgrade | |
Revenue Growth (YoY) | 510.85% | -1.91% | 34.76% | -98.86% | - | - | Upgrade |
Gross Profit | 2.31 | 0.31 | 0.31 | 0.23 | 20.38 | - | Upgrade |
Selling, General & Admin | 45.51 | 45.97 | 62.18 | 70.35 | 92.75 | 80.73 | Upgrade |
Research & Development | 52.4 | 54.11 | 60.4 | 74.31 | 47.96 | 11.41 | Upgrade |
Operating Expenses | 97.91 | 100.08 | 122.59 | 144.66 | 140.7 | 92.14 | Upgrade |
Operating Income | -95.6 | -99.77 | -122.27 | -144.43 | -120.33 | -92.14 | Upgrade |
Interest Expense | -3.12 | -3.12 | -2.66 | -0.92 | - | - | Upgrade |
Interest & Investment Income | 0.78 | 0.78 | 1.85 | 0.55 | 0.21 | 0.07 | Upgrade |
Earnings From Equity Investments | -0.03 | -2 | -3.59 | -16.01 | -58.56 | -76.51 | Upgrade |
Currency Exchange Gain (Loss) | -1.26 | -1.26 | -0.89 | 6.9 | 8.48 | -0.19 | Upgrade |
Other Non Operating Income (Expenses) | 15.56 | -9.06 | -1.61 | -0.21 | -0.34 | 0.01 | Upgrade |
EBT Excluding Unusual Items | -83.68 | -114.45 | -129.17 | -154.12 | -170.53 | -168.77 | Upgrade |
Merger & Restructuring Charges | -2 | -2 | -3.2 | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -40.4 | -40.4 | 86.29 | 0.3 | 4.58 | 19.86 | Upgrade |
Gain (Loss) on Sale of Assets | 4.63 | 4.63 | 0.16 | 1.48 | - | - | Upgrade |
Asset Writedown | -0.92 | -0.92 | - | - | - | - | Upgrade |
Other Unusual Items | 2.2 | 2.2 | 0.6 | 1.5 | 3.2 | -17.39 | Upgrade |
Pretax Income | -120.16 | -150.93 | -45.32 | -151.19 | -178.23 | -178.32 | Upgrade |
Income Tax Expense | -0.65 | -0.88 | -1.43 | 6.23 | -3.99 | 0.31 | Upgrade |
Earnings From Continuing Operations | -119.51 | -150.05 | -43.9 | -157.42 | -174.24 | -178.63 | Upgrade |
Minority Interest in Earnings | 0.11 | 0.78 | 3.67 | 5.03 | 6.44 | 8.78 | Upgrade |
Net Income | -119.4 | -149.27 | -40.22 | -152.39 | -167.81 | -169.84 | Upgrade |
Net Income to Common | -119.4 | -149.27 | -40.22 | -152.39 | -167.81 | -169.84 | Upgrade |
Shares Outstanding (Basic) | 174 | 160 | 159 | 156 | 138 | 93 | Upgrade |
Shares Outstanding (Diluted) | 174 | 160 | 159 | 156 | 138 | 93 | Upgrade |
Shares Change (YoY) | 7.97% | 0.83% | 2.00% | 12.62% | 48.64% | 973.40% | Upgrade |
EPS (Basic) | -0.69 | -0.93 | -0.25 | -0.98 | -1.21 | -1.83 | Upgrade |
EPS (Diluted) | -0.69 | -0.93 | -0.25 | -0.98 | -1.21 | -1.83 | Upgrade |
Free Cash Flow | - | -82.44 | -84.38 | -105.24 | -64.42 | -20.83 | Upgrade |
Free Cash Flow Per Share | - | -0.52 | -0.53 | -0.68 | -0.47 | -0.22 | Upgrade |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - | Upgrade |
Operating Margin | -4140.32% | -32393.51% | -38939.81% | -61987.12% | -590.52% | - | Upgrade |
Profit Margin | -5171.24% | -48463.96% | -12810.19% | -65401.29% | -823.56% | - | Upgrade |
Free Cash Flow Margin | - | -26767.21% | -26871.66% | -45167.38% | -316.15% | - | Upgrade |
EBITDA | -94.86 | -99.3 | -121.95 | -144.26 | -120.28 | -92.12 | Upgrade |
D&A For EBITDA | 0.74 | 0.47 | 0.32 | 0.17 | 0.05 | 0.02 | Upgrade |
EBIT | -95.6 | -99.77 | -122.27 | -144.43 | -120.33 | -92.14 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.